GERN compared with PRLD: revenue, margins and what each company keeps, and the suppliers and customers both name

GERNGeron Corp

Mkt capRevenueRevenue

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

Compare

GERNGeron Corp

PRLDPrelude Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

GERN

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.3%▼−3.68%×0.28

Q1 FY26±23.0%▼−11.79%×0.51

Q3 FY25±22.6%▼−5.22%×0.23

Aug 6 '25±28.3%▲+15.83%×0.56

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

= impliedGERN realized, solidPRLD realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

GERNGeron Corp

0.89▼−5.85%· post 0.89

Mkt cap$574.6MRevenue$57MQ2 FY26Revenue$184MFY25

PRLDPrelude Therapeutics Inc

3.89▼−5.01%· post 3.89

ClosedOct 30 '26

Mkt cap$309.6MRevenue$6MQ2 FY26Revenue—

Compare

ClosedOct 30 '26

GERNGeron Corp

PRLDPrelude Therapeutics Inc

0.89▼−5.85%post 0.89

Price

3.89▼−5.01%post 3.89

$574.6M

Mkt cap

$309.6M

Q2 FY26$57M

Revenue

$6MQ2 FY26

FY25$184M

Revenue

—

GERN0.89▼−5.85%vsPRLD3.89▼−5.01%ClosedOct 30 '26